Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Chun

Showing results (511-520 of 1,050) with videos related to

Pageof 105
Sort By:
Pathology, Research and Practice|January 9, 2023
The NeuroSAFE frozen section technique during radical prostatectomy - Implementation and optimization of technical aspects in a routine pathology workflowS Gretser, B Hoeh, M N Kinzler, et al.
European Urology|January 28, 2006
Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathologyFelix K-H Chun, Thomas Steuber, Andreas Erbersdobler, et al.
World Journal of Urology|November 2, 2024
Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Urologic Oncology|July 28, 2024
Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomyCarolin Siech, Benedikt Hoeh, Eike Rohlfsen, et al.
The Prostate|May 30, 2024
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patientsMike Wenzel, Benedikt Hoeh, Fabienne Hurst, et al.
Laryngoscope Investigative Otolaryngology|October 30, 2023
Establishment of novel immortalized middle ear cell lines as models for otitis mediaSimon Blaine-Sauer, Tina L Samuels, Pawjai Khampang, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
Cancer|July 11, 2006
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapyHeung T Kim, Ji-Youn Han, Dae H Lee, et al.
Pageof 105

Showing results (511-520 of 1,050) with videos related to

Sort By:
Pageof 105
Pathology, Research and Practice|January 9, 2023
The NeuroSAFE frozen section technique during radical prostatectomy - Implementation and optimization of technical aspects in a routine pathology workflowS Gretser, B Hoeh, M N Kinzler, et al.
European Urology|January 28, 2006
Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathologyFelix K-H Chun, Thomas Steuber, Andreas Erbersdobler, et al.
World Journal of Urology|November 2, 2024
Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Urologic Oncology|July 28, 2024
Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomyCarolin Siech, Benedikt Hoeh, Eike Rohlfsen, et al.
The Prostate|May 30, 2024
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patientsMike Wenzel, Benedikt Hoeh, Fabienne Hurst, et al.
Laryngoscope Investigative Otolaryngology|October 30, 2023
Establishment of novel immortalized middle ear cell lines as models for otitis mediaSimon Blaine-Sauer, Tina L Samuels, Pawjai Khampang, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
Cancer|July 11, 2006
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapyHeung T Kim, Ji-Youn Han, Dae H Lee, et al.
Pageof 105